Welcome to our dedicated page for Vanda Pharma news (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharma stock.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is a biopharmaceutical company whose news flow centers on FDA interactions, clinical trial results, product approvals, and financial performance. Recent press releases describe Vanda as a global biopharmaceutical company focused on therapies for high unmet medical needs, with commercial products including HETLIOZ, Fanapt, PONVORY, and NEREUS (tradipitant).
On this VNDA news page, readers can follow company announcements about regulatory milestones, such as FDA approvals, decision letters, and Biologics License Application or New Drug Application submissions. Examples include the FDA approval of NEREUS for the prevention of vomiting induced by motion, the submission of a BLA for imsidolimab in generalized pustular psoriasis, and updates on the collaborative framework with the FDA for HETLIOZ and tradipitant.
Investors and followers can also track clinical development updates, including topline data from randomized studies of tradipitant in GLP-1 agonist–induced nausea and vomiting, Phase 3 results in motion sickness, and long-term maintenance data for imsidolimab in generalized pustular psoriasis. Vanda’s news often highlights how these data support ongoing or planned regulatory submissions and potential new indications.
In addition, Vanda regularly issues financial and corporate communications, such as quarterly earnings releases, guidance updates, and notices of participation in investor conferences like the J.P. Morgan Healthcare Conference and the Stifel Healthcare Conference. These items provide context on product sales for Fanapt, HETLIOZ, and PONVORY, as well as commentary on commercial strategy and pipeline priorities.
By monitoring this VNDA news feed, readers can see how Vanda’s commercial performance, regulatory decisions, and clinical trial outcomes evolve over time across sleep-wake disorders, psychiatric illness, motion sickness, inflammatory skin disease, and treatment-related nausea and vomiting.
Vanda Pharmaceuticals (Nasdaq: VNDA) reported Q2 2021 financial results with total net product sales reaching $67.9 million, a 9% increase year-over-year. HETLIOZ® sales grew 7% to $44.5 million, while Fanapt® saw a 13% increase to $23.4 million. Net income was $9.7 million, up from $8.7 million in Q2 2020. For the first half of 2021, total sales rose 9% to $130.6 million, and cash reserves were $396.5 million. The Phase III trial of tradipitant for gastroparesis is nearing completion, with results expected by year-end 2021.
Vanda Pharmaceuticals (Nasdaq: VNDA) will release its second quarter 2021 financial results on July 28, 2021, after market close. A conference call is scheduled for 4:30 PM ET the same day to discuss the results and corporate activities. Investors can access the call by dialing 1-866-688-9426 for domestic calls or 1-409-216-0816 internationally. The call will also be available on the company's website, with a replay option from 7:30 PM ET on July 28 until 7:30 PM ET on August 4, 2021.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced its management will participate in upcoming investor conferences. These include the Bank of America Securities 2021 Virtual Health Care Conference on May 13, 2021, Oppenheimer Virtual Rare & Orphan Disease Summit on May 21, 2021, and Jefferies Virtual Healthcare Conference on June 2, 2021. Investors can access the conferences via the company's corporate website, with archive links available for 30 days post-event. Vanda focuses on developing therapies to address significant medical needs.
Vanda Pharmaceuticals (Nasdaq: VNDA) reported strong first-quarter results for 2021, with total net product sales reaching $62.7 million, an 8% increase year-over-year. Key revenue contributors included HETLIOZ® at $39.3 million (up 11%) and Fanapt® at $23.3 million (up 3%). The company achieved an income before taxes of $10.4 million compared to $1.2 million in 2020. Vanda also provided 2021 guidance, forecasting total revenues between $270 million and $300 million.
Vanda Pharmaceuticals Inc. (VNDA) will release its Q1 2021 financial results on May 5, 2021, after market close. A conference call is scheduled for 4:30 PM ET on the same day to discuss the results and corporate activities. Investors can participate by calling 1-866-688-9426 (domestic) or 1-409-216-0816 (international), using passcode 5709209. The call will also be available online and archived on the company's website. A replay will be accessible from 7:30 PM ET on May 5 until 7:30 PM ET on May 12, 2021.
Vanda Pharmaceuticals (Nasdaq: VNDA) reported fourth quarter and full year 2020 results, achieving record commercial revenue of $67.7 million in Q4, an 11% increase year-over-year. HETLIOZ® sales rose 14% to $44.2 million, while Fanapt® sales increased 5% to $23.5 million. Despite a drop in annual net income to $23.3 million from $115.6 million in 2019, Vanda holds $367.7 million in cash. Looking ahead, the company projects 2021 revenues between $270-$300 million, with HETLIOZ® and Fanapt® sales expected to reach $180-$200 million and $90-$100 million, respectively.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) will release its fourth quarter and full year 2020 results on February 10, 2021, after market close. Management will discuss these results during a conference call at 4:30 PM ET on the same day, with participation details provided. A replay will be available until February 17, 2021. Vanda focuses on developing innovative therapies to address unmet medical needs and improve patient lives. For more information, visit www.vandapharma.com.
Vanda Pharmaceuticals (VNDA) announced FDA approval for HETLIOZ® (tasimelteon) to treat nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS). This marks HETLIOZ® as the first medication approved for SMS, a rare disorder affecting sleep due to an inverted circadian rhythm. The approval is based on a placebo-controlled study showing efficacy in both adults and children. HETLIOZ® capsules are available immediately, while the liquid formulation for children is expected in Q1 2021. Vanda aims to address significant sleep-related challenges for SMS patients.
Vanda Pharmaceuticals (Nasdaq: VNDA) reported Q3 2020 net product sales of $60.3 million, up 1% year-over-year. HETLIOZ® sales grew 5% to $39.6 million, while Fanapt® sales fell 6% to $20.7 million. Income before taxes decreased to $8.4 million from $12.3 million in Q3 2019. For the first nine months, revenue increased 9% to $180.5 million, with HETLIOZ® sales rising 12%. Cash reserves grew to $348.5 million. Upcoming FDA decisions include priority reviews for HETLIOZ® in treating Smith-Magenis Syndrome, with a target date of December 1, 2020.
Vanda Pharmaceuticals (NASDAQ: VNDA) announced FDA approval for its Investigational New Drug (IND) application for VSJ-110, a CFTR activator, aimed at treating allergic conjunctivitis. This milestone marks a key collaboration with UCSF and initiates a Phase II clinical study to assess VSJ-110's anti-inflammatory effects and its potential to increase tear production. With 16 million individuals in the U.S. affected by dry eye, this drug could address a significant unmet medical need. Results from the study are expected in 2021.